June 18, 2010, Valencia, Spain
Partner Release:
GILEAD’S HEAD-TO-HEAD STUDY OF CAYSTON® VERSUS TOBRAMYCIN INHALATION SOLUTION IN CYSTIC FIBROSIS PATIENTS ACHIEVES CO-PRIMARY EFFICACY ENDPOINT OF NON-INFERIORITY [more]
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
June 17, 2010, Monmouth Junction, NJ
Partner Release:
Transave, Inc., today reported interim
results from a multi-cycle Phase II open label clinical trial in cystic fibrosis (CF) patients
on its lead investigational drug, ARIKACETM (liposomal amikacin for inhalation). [more]
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
May 24, 2010, Monmouth Junction, NJ
Partner Release:
Transave Inc. today announced that the United States Patent and Trademark Office has issued an important composition of matter patent (U.S. Patent No. 7,718,189) for liposomal aminoglycoside formulations including its lead compound, ARIKACE™ (liposomal amikacin for inhalation). The company expects that the patent will provide exclusivity for ARIKACE until October 1, 2026. [more]
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
May 17, 2010, San Diego, CA
Partner Release:
Mpex Pharmaceuticals, Inc. today announced the
presentation of data from its Phase 2b clinical trial with AeroquinTM (a proprietary aerosol formulation of levofloxacin, MP-376) in cystic fibrosis (CF) at the American Thoracic Society (ATS) Annual Meeting in New Orleans. [more]
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
February 23, 2010, Monterey, California
PARI Pharma’s Altera Delivers Gilead’s Cayston, Approved by the U.S. FDA for the Improvement of Respiratory Symptoms in Cystic Fibrosis Patients with Pseudomonas Aeruginosa [more]
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
February 22, 2010, Foster City, California
Partner Release:
U.S. Food and Drug Administration Approves Cayston(R) (Aztreonam for Inhalation Solution) for the Improvement of Respiratory Symptoms in Cystic Fibrosis Patients with Pseudomonas Aeruginosa [more]
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
February 22, 2010, Cambridge, Massachusetts
Alnylam Initiates Phase IIb Clinical Trial of ALN-RSV01 in Adult Lung Transplant Patients Infected with Respiratory Syncytial Virus (RSV) Infection [more]
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
February 11, 2010, Monterey, California
PARI Pharma Enrolls First Patient in Phase 2b Study of L-CsA [more]
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Partner Press Release
Kamada Announces Enrollment of First Patient in Its Pivotal Study for Inhaled AAT in Europe
Mon, 08 Feb 2010 - NESS ZIONA, Israel - (Business Wire) Kamada, a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced today that it has enrolled the first patient into its pivotal clinical trial with
its new breakthrough compound of inhaled alpha-1 antitrypsin (AAT) delivered by an Investigational eFlow Nebulizer System (PARI Pharma GmbH), in patients with alpha-1 antitrypsin deficiency. [more]
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
September 23, 2009, Monterey, California
PARI’s Altera Delivers Gilead’s Cayston, Approved by European Commission to Treat Cystic Fibrosis [more]
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
September 14, 2009, Monterey, California
Mpex Reports Positive Phase II Results with Aeroquin, Delivered by PARI Pharma’s eFlow Technology [more]
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
June 2, 2009, Monterey, California
PARI Pharma Reports Successful Phase Ib Clinical Results for Inhaled Liposomal Cyclosporine A and Gains FDA Orphan Drug Designation for the Prevention and Treatment of Bronchiolitis Obliterans [more]
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
May 20, 2009, Munich, Germany and Monterey, California
PARI Pharma’s Nebulized DSCG Shows Results Similar to Inhaled Steroids in Asthma Studies Presented at ATS [more]
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
May 7, 2009, Munich, Germany and Monterey, California
PARI Pharma Receives 2nd ODD from EMEA; Moves Inhaled Tobramycin – eFlow Technology Program Forward [more]
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
March 17, 2009,
Ness Ziona, Israel
Kamada Completes Last Patient Visit in Phase II
Bronchiectasis Study with its Inhaled AAT
[more]
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
November 10, 2008,
Monterey, California
PARI Pharma
Completes Successful Clinical Trials for
Tobramycin 100 & Investigational eFlow for CF
[more]
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
December 13, 2007,
Monterey, California
PARI’s eFlow
delivers Alnylam RNAi Therapeutic in Phase I
study
[more]
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
November 26, 2007,
Monterey, California
PARI’s eFlow
included in Gilead’s NDA Submission for
Aztreonam Lysine for Inhalation
[more]
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
May 29, 2007, Foster City, CA
Gilead Announces Achievement of Primary
Efficacy Endpoint in Second Phase III Study of
Aztreonam Lysine for Inhalation in Patients with
Cystic Fibrosis[more]
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
March 28, 2007, Munich Germany
PARI Pharma, New Name of PARI Aerosol
Research Institute [more]
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
January 3, 2007, Monterey, California
PARI’s eFlow Wins Good Design Award [more]
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
December 4, 2006, Monterey, California
NIH using PARI’s eFlow in HIV/AIDS Vaccine
Research [more]
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
November 29, 2006, Monterey, California
PARI’s eFlow in Cystic Fibrosis Clinical
Trial of L-arginine [more]
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
November 20, 2006, Monterey, California
PARI and Kamada Collaborate to Develop
Inhaled Alpha-1 Antitrypsin
[more]
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
October 16, 2006, Monterey, California
PARI’s eFlow Nebulizer used in Alnylam
Clinical Trial for Respiratory Syncytial Virus;
New Drug Based on RNAi Technology [more]
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
June 19, 2006, Midlothian, Virginia
PARI Named Leading Nebulizer Company in
Cambridge Consulting Survey; Market Dominance
Also Visible with Frost & Sullivan Award for
Product Innovation
[more]
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
May 17, 2006, Midlothian, Virginia
PARI Celebrates 100 Years of Aerosol Therapy [more]
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
April 10, 2006. Monterey, California
PARI Pharma receives
Medical Design Excellence Award for eFlow
Nebulizer [more]
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
April 6,
2006. Gemünden and Munich, Germany
Activaero and PARI combine technologies to create
controlled breath nebulizer [more]
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
April 6, 2006. Biotech Business
Week
Related Kamada Press Release [more]
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
January 24, 2006. Monterey, California
PARI Pharma and Kamada to
develop Inhaled Emphysema Therapy [more]
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
November 15, 2005. Monterey, California
PARI to present eFlow Development at Medical
Plastics Seminar; Discussion of a Customizable
Platform for New Inhaled Drug Formulations [more]
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
November 14, 2005. Monterey, California
PARI Issued US Patent for eFlow; Device
Innovations Lead to Greater Efficiency in Drug
Delivery [more]
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
July 29, 2005. Munich, Germany
PARI’s Inhaled Cyclosporin Granted Orphan
Status in EU [more]
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
October 20, 2004. Monterey, California
PARI Pharma’s Formulation
Work and eFlow Featured in Corus Pharma’s
Positive Phase II Trial Results --
Marks Greater Headway in Drug/Device Matching [more]
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
August 23, 2004. Monterey, California
PARI Granted Orphan Drug Designation for
Inhaled Cyclosporine – Potential New Therapy for
Lung Transplant Patients [more]
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
April 25, 2004. Monterey, California
Corus Pharma’s Phase III Trial for Cystic
Fibrosis Drug is
First to Feature PARI’s eFlow --
Marks Customization in Drug/Device Matching [more] |